Bifogade filer
Xspray Pharma receives declaration of intent from Östersjöstiftelsen regarding exercise of TO6 warrants
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Xspray Pharma has received a written declaration of intent whereby Östersjöstiftelsen which owns 11.9 percent of shares in the company state their intent to exercise TO6 warrants to subscribe for newly issued shares for the subscription price 40.00 SEK per share. On April 10, 2024, the company announced similar declarations of intent from other large owners in the company. Thereby owners of a total of approximately 62 percent of shares have stated their intent to exercise TO6 warrants. If all outstanding TO6 warrants are used to subscribe for new shares, the company raises proceeds of SEK 125.5 million before transaction costs.
“We are very pleased that all our larger shareholders show continued confidence in Xspray and our commercialization plan. During the coming months we are planning to take the final decisive steps to launch Dasynoc®, our first commercial product based on our patented platform technology which can improve a number of life supporting cancer therapies,” says Per Andersson, CEO of Xspray Pharma.
The subscription period for the TO6 warrants is ongoing and will last until May 2, 2024 and the last day of trading of TO6 warrants is April 29, 2024. If all outstanding TO6 warrants are used to subscribe for new shares, the company raises SEK 125.5 million before transaction costs.